Global Companion Animal Vaccine Market is valued at USD 3074.9 Million in 2021 and is expected to reach USD 4873.3 Million by 2028 with a CAGR of 6.8% over the forecast period.
Global Companion Animal Vaccine Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028- Increasing adoption of companion animals, growing number of research & development activities of novel companion animal vaccines and rising number of nuclear families are major factors anticipated to drive the growth of Global Companion Animal Vaccines Market.
Animals are additionally the transporters of different infections and diseases that could be shrunk by people around them. And, companion animals likewise stand the risk of contracting contaminations or diseases from people around them. Vaccination is thus a significant perspective that animal owners are asked not to neglect for the security of both the pets and owners the same. Companion animal vaccines assume an essential part in guaranteeing longevity, great health and in working on overall productivity of pets in a cost-effective way. Companion animal vaccines diminish transmission of different sicknesses from animals to humans. Companion animal vaccines are parenteral items that are utilized in prophylactic treatment of different sicknesses, for example, blastomycosis, psittacosis cat scratch infection and others. The major goals of companion vaccines are to improve the health and welfare of companion animals, increase production of livestock in a cost-effective manner, and prevent animal-to-human transmission from both domestic animals and wildlife. The companion animal vaccines are important for protection against serious disease to pet animal.
The Covid-19 pandemic has shown a significant impact on the growth of global companion animal vaccine market. During Covid-19 pandemic, the animal vaccination drive was slowed down because of travelling restrictions and supply chain disruptions caused reduced patient visits to the veterinary clinics. Most veterinary research centers are effectively associated with testing Covid-19 in people to defeat the lack of medical care facilities and Covid-19 testing labs, internationally. However, during lockdown many dog pets were adopted and the growth of global companion animal vaccines shown increase after lockdown was lifted. The veterinary clinics were augmented pet ownership during the lockdown period which has positively impacted the growth of the market.
The global companion animal vaccine market is segmented into on the basis of vaccine type, animal type, and distribution channel and region & country level. On the basis of type, the global companion animal vaccine market inactivated vaccine, live attenuated vaccine, recombinant vaccine, subunit recombinant vaccine, conjugate vaccine, DNA vaccine, toxoid vaccine and others. On the basis animal type, the market is classified into dogs, cats and others. On the basis of distribution channel, the global companion animal vaccine market is divided into veterinary hospital, veterinary clinic, veterinary research institute and retail pharmacy.
Some of the key players for global companion animal vaccine market are
On September 16th, 2020; Applied DNA Sciences, Inc. announced that Applied DNA Sciences, Inc and Evvivax, S.R.L., a twist out of Takis Biotech focused on designed veterinary immunotherapy and vaccines, are relied upon to start a veterinary clinical preliminary of one of the Company's five LineaDNA vaccine candidates upon approval of the clinical arrangement by the U.S. Department of Agriculture. The objective of the vaccine preliminary is to assess the vaccine applicant as a strategy for the anticipation of SARS-CoV-2 (Covid-19) (a zoonotic sickness) contaminations in companion cats of humans. The clinical preliminary will try to comprehend the immune reaction in cats by using a vaccination procedure of interest in individuals that could yield significant information for the both cats and humans.
Increasing Adoption of Companion Animals, Growing Number of Research & Development Activities for Novel Companion Animal Vaccines and Rising Number of Nuclear Families are Driving the Market Growth
One of the major factors driving the growth of global companion animal vaccines market is increasing of adoption of companion animals. The rising reception of companion, like cats and dogs, and the growing instances of zoonotic infections drives the market development. A number of diseases resulting from contact with animals like its feces, bodily fluids fur, hair, feathers, scales, or skin, its food; or through contact with the animal’s environment are infectious to human. Thus, pet animals are vaccinated to avoid these incidences. Hence, increasing incidences of animal contact disease outbreak will drive the market growth. For example; as indicated by the yearly report of the European Pet Food Industry Association (FEDIAF) in 2020; about of 85 million European families owns at least one pet animal.
In addition, growing number of research & development activities for novel companion animal vaccines are also supplementing the market growth. Biotechnology made advancement in vaccines to increase the immunity and contributed significantly in the development and design of vaccines. For example; in December 2019; Merck Animal Health launched two new vaccines, to be specific the Nobivac EDGE DAPPV + L4, a combo vaccine to incorporate parainfluenza security, and the Nobivac EDGE DAPPV combo immunization to keep in mind parainfluenza assurance for dogs.
Furthermore, rising number of nuclear families also drives the global companion animal vaccines market. Pets are vital part of many families which gives emotional support and a sense of pleasure to dog owners. Rising numbers of nuclear families prefer the adoption of pets for security. Hence, increased pet adoption will raise the pet vaccination which drives the market growth. However, lack of awareness regarding animal vaccination especially in emerging economies of the world may hamper the growth of the global companion animal vaccines market. In spite of that, increasing investment and advancements in this field may provide more opportunities for the further growth of the market.
North America is expected to dominate the global companion animal vaccines market due to the rising adoption of companion animals, high awareness about animal vaccines and presence of key players in this region. For example; according to the National Institute of Statistics and Geography (INEGI) 2019; around 70% of Mexican families had something like one pet. Such high reception in the region is driving the development of market. Presence of key companies also drive the market growth in this region. For instance; in September 2020; Applied DNA Sciences Inc. and Evvivax SRL announced their arrangements to start a veterinary clinical preliminary for LineaDNA vaccine competitors after getting approval for the clinical arrangement from the US Department of Agriculture. The objective of the vaccine trial is to assess the vaccine applicant as a strategy for avoiding the Covid-19 (a zoonotic illness) contamination in companion cats of humans.
Asia Pacific is the fastest growing region for the global companion animal vaccines market due to increasing pet adoption especially in the countries like India, ongoing research in animal vaccines and rising zoonotic diseases in this region. For instance; according to NCBI (National Center of Biotechnology and Information), there are about 25,000–30,000 Indians died from rabies every year.
Middle East and Africa
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2028|
|Market Size in 2021:||USD 3074.9 Million|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2028:||USD 4873.3 Million|
|Tables, Charts & Figures:||175|
|Companion Animal Vaccines Companies:||Bayer, Merial, Vetoquinol, Boehringer Ingelheim GmbH, Biogénesis Bagó, Elanco Animal Health Incorporated, Ceva, Virbac, Zoetis Inc., Merck & Co., Inc., HIPRA, Ourofino Animal Health and others.|
|Segments Covered||By Type, By Animal Type, By Distribution Channel|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us email@example.comJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2023-24 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®